Case Report: Trazodone as a possible treatment for psychiatric adverse events related to ALK inhibitors

Frontiers in Psychiatry 2026 Open access

Read full text
Authors: Luca Persico, Andrea Miuli, Stefania Chiappini, Alessio Mosca, Michele De Tursi, Mauro Pettorruso, Giovanni Martinotti
DOI: 10.3389/fpsyt.2026.1718767
Cited by: 1
References: 21

Abstract

Introduction: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the first-line treatment of ALK-positive metastatic non-small cell lung cancer, frequently associated with psychiatric adverse events. Method: This study presents the clinical case of a patient who was successfully treated with low-dose trazodone for lorlatinib-induced psychiatric symptoms. In addition, an overview of the existing literature on the management of psychiatric adverse events (AEs) associated with ALK inhibitors is provided. Results and conclusions: Based on the evidence presented and the preliminary outcomes observed in the reported case, this study aims to outline a management strategy for lorlatinib-related psychiatric complications.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Advanced Breast Cancer Therapies Lung Cancer Research Studies

Publication details

Journal / source
Frontiers in Psychiatry
Publisher
Frontiers Media SA
Volume
17
Pages
1718767–1718767
Publication date
30 June 2026
Language
EN